AI assistant
Teva Pharmaceutical Industries Ltd. — Director's Dealing 2023
Mar 2, 2023
7082_dirs_2023-03-02_ecdea6a9-bd15-4a35-9eaa-e7cfb47dd8b6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK: 0000818686
Period of Report: 2023-02-28
Reporting Person: Shani Eli (EVP,Global Marketing&Portfolio)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-02-28 | Ordinary Shares | M | 5311 | — | Acquired | 25052 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-02-28 | Restricted Share Units | $ | M | 5311 | Disposed | Ordinary Shares (5311) | Direct |
Footnotes
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources
and Compensation Committee, the cash value of one ordinary share.
F3: Restricted share units were granted on February 28, 2020 with 5,311 vested on each of February 28, 2021, February 28, 2022 and February 28, 2023 and 5,312 vesting on February 28, 2024.